Literature DB >> 32214446

Pharmacists' Perceptions on Their Role, Activities, Facilitators, and Barriers to Practicing in a Post-Intensive Care Recovery Clinic.

Antoinette B Coe1, Rebecca E Bookstaver2, Andrew C Fritschle3, Michael T Kenes2, Pamela MacTavish4, Rima A Mohammad1,5, Robert J Simonelli6, Jessica A Whitten3, Joanna L Stollings7.   

Abstract

Background: Complex medication regimen changes burden intensive care unit (ICU) survivors and their caregivers during the transition to home. Intensive care unit recovery clinics are a prime setting for pharmacists to address patients' and their caregivers' medication-related needs. The purpose of this study was to describe ICU recovery clinic pharmacists' activities, roles, and perceived barriers and facilitators to practicing in ICU recovery clinics across different institutions.
Methods: An expert panel of ICU recovery clinic pharmacists completed a 15-item survey. Survey items addressed the pharmacists' years in practice, education and training, activities performed, their perceptions of facilitators and barriers to practicing in an ICU recovery clinic setting, and general ICU recovery clinic characteristics. Descriptive statistics were used.
Results: Nine ICU recovery clinic pharmacists participated. The average number of years in practice was 16.5 years (SD = 13.5, range = 2-38). All pharmacists practiced in an interprofessional ICU recovery clinic affiliated with an academic medical center. Seven (78%) pharmacists always performed medication reconciliation and a comprehensive medication review in each patient visit. Need for medication education was the most prevalent item found in patient comprehensive medication reviews. The main facilitators for pharmacists' successful participation in an ICU recovery clinic were incorporation into clinic workflow, support from other health care providers, and adequate space to see patients. The ICU recovery clinic pharmacists perceived the top barriers to be lack of dedicated time and inadequate billing for services. Conclusions: The ICU recovery clinic pharmacists address ICU survivors' medication needs by providing direct patient care in the clinic. Strategies to mitigate pharmacists' barriers to practicing in ICU recovery clinics, such as lack of dedicated time and adequate billing for pharmacist services, warrant a multifaceted solution, potentially including advocacy and policy work by national pharmacy professional organizations.
© The Author(s) 2019.

Entities:  

Keywords:  ICU recovery clinic; barriers; facilitators; pharmacist

Year:  2019        PMID: 32214446      PMCID: PMC7081480          DOI: 10.1177/0018578718823740

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN: 0018-5787


  32 in total

Review 1.  Critical care delivery in the intensive care unit: defining clinical roles and the best practice model.

Authors:  R J Brilli; A Spevetz; R D Branson; G M Campbell; H Cohen; J F Dasta; M A Harvey; M A Kelley; K M Kelly; M I Rudis; A C St Andre; J R Stone; D Teres; B J Weled
Journal:  Crit Care Med       Date:  2001-10       Impact factor: 7.598

2.  Inappropriate discharge on bronchodilators and acid-blocking medications after ICU admission: importance of medication reconciliation.

Authors:  Andrey Pavlov; Rostislav Muravyev; Yaw Amoateng-Adjepong; Constantine A Manthous
Journal:  Respir Care       Date:  2014-05-20       Impact factor: 2.258

3.  Association of ICU or hospital admission with unintentional discontinuation of medications for chronic diseases.

Authors:  Chaim M Bell; Stacey S Brener; Nadia Gunraj; Cindy Huo; Arlene S Bierman; Damon C Scales; Jana Bajcar; Merrick Zwarenstein; David R Urbach
Journal:  JAMA       Date:  2011-08-24       Impact factor: 56.272

4.  Inappropriate medication prescriptions in elderly adults surviving an intensive care unit hospitalization.

Authors:  Alessandro Morandi; Eduard Vasilevskis; Pratik P Pandharipande; Timothy D Girard; Laurence M Solberg; Erin B Neal; Tyler Koestner; Renee E Torres; Jennifer L Thompson; Ayumi K Shintani; Jin H Han; John F Schnelle; Donna M Fick; E Wesley Ely; Sunil Kripalani
Journal:  J Am Geriatr Soc       Date:  2013-07       Impact factor: 5.562

5.  Implications of atypical antipsychotic prescribing in the intensive care unit.

Authors:  Bridgette L Kram; Shawn J Kram; Kelli R Brooks
Journal:  J Crit Care       Date:  2015-04-08       Impact factor: 3.425

6.  Impact of a clinical pharmacist-enforced intensive care unit sedation protocol on duration of mechanical ventilation and hospital stay.

Authors:  John Marshall; Christine A Finn; Arthur C Theodore
Journal:  Crit Care Med       Date:  2008-02       Impact factor: 7.598

7.  Clinical and economic outcomes of involving pharmacists in the direct care of critically ill patients with infections.

Authors:  Robert MacLaren; C A Bond; Steven J Martin; David Fike
Journal:  Crit Care Med       Date:  2008-12       Impact factor: 7.598

8.  Critical Care Pharmacists and Medication Management in an ICU Recovery Center.

Authors:  Joanna L Stollings; Sarah L Bloom; Li Wang; E Wesley Ely; James C Jackson; Carla M Sevin
Journal:  Ann Pharmacother       Date:  2018-02-18       Impact factor: 3.154

9.  ICU admission characteristics and mortality rates among elderly and very elderly patients.

Authors:  Lior Fuchs; Catherine E Chronaki; Shinhyuk Park; Victor Novack; Yael Baumfeld; Daniel Scott; Stuart McLennan; Daniel Talmor; Leo Celi
Journal:  Intensive Care Med       Date:  2012-07-14       Impact factor: 17.440

10.  Evaluation of discontinuation of atypical antipsychotics prescribed for ICU delirium.

Authors:  Karalea D Jasiak; Ellen A Middleton; James M Camamo; Brian L Erstad; Linda S Snyder; Yvonne C Huckleberry
Journal:  J Pharm Pract       Date:  2012-11-26
View more
  1 in total

Review 1.  Addressing the post-acute sequelae of SARS-CoV-2 infection: a multidisciplinary model of care.

Authors:  Ann M Parker; Emily Brigham; Bronwen Connolly; Joanne McPeake; Anna V Agranovich; Michael T Kenes; Kelly Casey; Cynthia Reynolds; Konrad F R Schmidt; Soo Yeon Kim; Adam Kaplin; Carla M Sevin; Martin B Brodsky; Alison E Turnbull
Journal:  Lancet Respir Med       Date:  2021-10-19       Impact factor: 30.700

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.